ASCO 2015 Highlights

Based on results of a study presented at ASCO 2018, the presence of an MSI-H or dMMR tumor signature, regardless of cancer type or family history, should prompt genetic testing to evaluate for Lynch syndrome.

Chicago, IL—Healthcare costs in the United States have spiraled out of control, and polls show that single-payer healthcare is gaining traction.

“NGS decreased the cost of testing, identified the highest percentage of targetable genetic alterations, and had the fastest turnaround,” reported Nathan A. Pennell, MD, PhD.

“These promising results underscore the importance of screening for these alterations in the clinic. The activity of LOXO-292 is durable, with over 90% of patients still on treatment as of the data cutoff,” said Alexander E. Drilon, MD.